---
document_datetime: 2024-11-06 09:29:57
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pemetrexed-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pemetrexed-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 0.9481763
conversion_datetime: 2025-12-23 02:20:13.648675
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - | 04/09/2024                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Pemetrexed Sandoz Procedural steps taken and scientific information after the authorisation* *Due to Agency`s update of its procedure management systems, an additional document, capturing the historical lifecycle may be available in the 'Assessment history' section. For the complete lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) . Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->